Guidant CE-marks new stent platform:
This article was originally published in Clinica
Guidant has gained European go-ahead to sell its MULTI-LINK ZETA sixth generation stent platform for treating coronary artery disease. The ZETA device incorporates a delivery platform that features a softer, more flexible balloon material. It is designed to enhance delivery to the site of the artery blockage and promote smooth deployment, said the Indianapolis, Indiana firm. The system is based on the firm's multi-link penta stent, which was launched last year.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.